Daiichi Sankyo funded the study and participated in the study design, data collection, data analysis, and data interpretation, and provided the study drug; assisted in writing the report; and approved ...

A randomized, double-blind, three-arm, parallel group, phase 1 study to assess the pharmacokinetics ... RCT T-DXd vs T-DMi 524 54.3 RCT: Randomised controlled trial. T-DXd: Trastuzumab Deruxtecan.

Despite the lack of a study directly comparing trastuzumab deruxtecan and trastuzumab rezetecan ... have a similar type of drug and study design, the same primary endpoint and line of treatment ...

In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy ...

The other study, also published in the New England Journal of Medicine last week, found that the experimental drug conjugate called trastuzumab deruxtecan was able to substantially reduce tumor ...

Researchers designed DESTINY-Breast02 as a confirmatory study to assess trastuzumab deruxtecan vs. physician’s choice of treatment for 608 patients whose metastatic breast cancer progressed ...

Study participants were randomly assigned to receive trastuzumab deruxtecan monotherapy, trastuzumab deruxtecan followed by THP, or standard of care (doxorubicin and cyclophosphamide followed by ...

Woman Receiving Radiation Therapy Treatments for Breast Cancer Trastuzumab deruxtecan significantly ... arm and 15.3 months for the T-DM1 arm. The study’s primary endpoint was PFS, and secondary ...

The randomized phase 3 trial is looking at whether trastuzumab deruxtecan (Enhertu; Daiichi Sankyo, AstraZeneca), with or without pertuzumab, would be better than the standard-of-care regimen in ...

Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a ...